Please ensure Javascript is enabled for purposes of website accessibility
New Studies Clarify What Drugs Help, Hurt for COVID-19
gvw_ap_news
By Associated Press
Published 5 years ago on
July 19, 2020

Share

Fresh studies give more information about what treatments do or don’t work for COVID-19, with high-quality methods that give reliable results.
British researchers on Friday published their research on the only drug shown to improve survival — a cheap steroid called dexamethasone. Two other studies found that the malaria drug hydroxychloroquine does not help people with only mild symptoms.
For months before studies like these, learning what helps or harms has been undermined by “desperation science” as doctors and patients tried therapies on their own or through a host of studies not strong enough to give clear answers.
“For the field to move forward and for patients’ outcomes to improve, there will need to be fewer small or inconclusive studies” and more like the British one, Drs. Anthony Fauci and H. Clifford Lane of the National Institutes of Health wrote in the New England Journal of Medicine.
It’s now time to do more studies comparing treatments and testing combinations, said Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in New York.
Here are highlights of recent treatment developments:

Dexamethasone

The British study, led by the University of Oxford, tested a type of steroid widely used to tamp down inflammation, which can become severe and prove fatal in later stages of COVID-19.
About 2,104 patients given the drug were compared to 4,321 patients getting usual care.
It reduced deaths by 36% for patients sick enough to need breathing machines: 29% on the drug died versus 41% given usual care. It curbed the risk of death by 18% for patients needing just supplemental oxygen: 23% on the drug died versus 26% of the others.
However, it seemed harmful at earlier stages or milder cases of illness: 18% of those on the drug died versus 14% of those given usual care.
The clarity of who does and does not benefit “probably will result in many lives saved,” Fauci and Lane wrote.

Hydroxychloroquine

The same Oxford study also tested hydroxychloroquine in a rigorous manner and researchers previously said it did not help hospitalized patients with COVID-19.
After 28 days, about 25.7% on hydroxychloroquine had died versus 23.5% given usual care — a difference so small it could have occurred by chance
Now, details published on a research site for scientists show that the drug may have done harm. Patients given hydroxychloroquine were less likely to leave the hospital alive within 28 days — 60% on the drug versus 63% given usual care. Those not needing breathing machines when they started treatment also were more likely to end up on one or to die.
Two other experiments found that early treatment with the drug did not help outpatients with mild COVID-19.
study of 293 people from Spain published in the journal Clinical Infectious Diseases found no significant differences in reducing the amount of virus patients had, the risk of worsening and needing hospitalization, or the time until recovery.
A similar study by University of Minnesota doctors in Annals of Internal Medicine of 423 mildly ill COVID-19 patients found that hydroxychloroquine did not substantially reduce symptom severity and brought more side effects.
“It is time to move on” from treating patients with this drug, Dr. Neil Schluger from New York Medical College wrote in a commentary in the journal.

Photo of hydroxychloroquine tablets
FILE – In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)

Remdesivir

The only other therapy that’s been shown to help COVID-19 patients is remdesivir, an antiviral that shortens hospitalization by about four days on average.
“The role of remdesivir in severe COVID is now what we need to figure out,” Memorial Sloan Kettering’s Bach wrote in an email, saying the drug needs to be tested in combination with dexamethasone now.
Details of the government-led remdesivir study have not yet been published, but researchers are eager to see how many patients received other drugs such as steroids and hydroxychloroquine.
Meanwhile, Gilead Sciences, the company that makes remdesivir, which is given as an IV now, has started testing an inhaled version that would allow it to be tried in less ill COVID-19 patients to try to keep them from getting sick enough to need hospitalization. Gilead also has started testing remdesivir in a small group of children.
Supplies are very limited, and the U.S. government is allocating doses to hospitals through September.

Photo of a vial of the investigational drug remdesivir
In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Young Democrats Offer Lessons for Their Leaders at Party Convention

DON'T MISS

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

DON'T MISS

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

DON'T MISS

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

DON'T MISS

Musk Calls Trump’s Big Beautiful Bill ‘a Disgusting Abomination’

DON'T MISS

US Tariffs Could Put Air Safety at Risk, Aerospace and Airline Industries Warn

DON'T MISS

Trump to Sign Order Doubling Metals Tariffs, White House Says

DON'T MISS

California Inmate Gets Five Years for Role in Drone Drug Smuggling Scheme

DON'T MISS

Millions Invested in Land for Innovation Village. Will It Be a Fresno Game-Changer?

DON'T MISS

Trump Threatens California With Fines After Trans Athlete Wins Girls’ State Titles

UP NEXT

American Doctors Are Moving to Canada To Escape the Trump Administration

UP NEXT

Loretta Swit, Emmy-winner Who Played Houlihan on Pioneering TV Series ‘M.A.S.H.,’ Has Died at 87

UP NEXT

1 in 4 US Children Have Parents With Substance Use Disorder, Study Finds

UP NEXT

Dozens Sickened in Expanding Salmonella Outbreak Linked to Recalled Cucumbers

UP NEXT

Speaker Johnson Raises Campaign Money in Fresno

UP NEXT

Business Insider Cuts 21% of Workforce, Memo Shows

UP NEXT

Harvard Agrees to Relinquish Early Photos of Slaves, Ending a Long Legal Battle

UP NEXT

Silence on E. Coli Outbreak Highlights How Trump Team’s Changes Undermine Food Safety

UP NEXT

Trump Pardons Tax Cheat After Mother Attends $1 Million Dinner

UP NEXT

NPR Sues Trump Administration Over Executive Order to Cut Funding

US Judge Dismisses California’s Tariff Lawsuit, Teeing up Appeal

5 hours ago

Young Democrats Offer Lessons for Their Leaders at Party Convention

6 hours ago

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

6 hours ago

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

7 hours ago

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

7 hours ago

Musk Calls Trump’s Big Beautiful Bill ‘a Disgusting Abomination’

7 hours ago

US Tariffs Could Put Air Safety at Risk, Aerospace and Airline Industries Warn

8 hours ago

Trump to Sign Order Doubling Metals Tariffs, White House Says

8 hours ago

California Inmate Gets Five Years for Role in Drone Drug Smuggling Scheme

8 hours ago

Millions Invested in Land for Innovation Village. Will It Be a Fresno Game-Changer?

8 hours ago

Clovis Unified Families ‘Resigned’ To Grad Ceremony Ban, Attorney Says

Barring any last-minute about-faces by Clovis Unified officials, eight high school seniors won’t be joining their classmates at their ...

2 hours ago

2 hours ago

Clovis Unified Families ‘Resigned’ To Grad Ceremony Ban, Attorney Says

3 hours ago

Hegseth Orders the Name of Gay Rights Activist Harvey Milk Scrubbed From Navy Ship

3 hours ago

Knicks Fire Coach Tom Thibodeau After First Eastern Conference Finals Berth in 25 Years

U.S. President Donald Trump holds a chart next to U.S. Secretary of Commerce Howard Lutnick as Trump delivers remarks on tariffs in the Rose Garden at the White House in Washington, D.C., U.S., April 2, 2025. REUTERS/Carlos Barria/File Photo
5 hours ago

US Judge Dismisses California’s Tariff Lawsuit, Teeing up Appeal

6 hours ago

Young Democrats Offer Lessons for Their Leaders at Party Convention

6 hours ago

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

7 hours ago

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

7 hours ago

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

Help continue the work that gets you the news that matters most.

Search

Send this to a friend